These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9197929)

  • 1. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients.
    Hu YJ; Chen Y; Zhang YQ; Zhou MZ; Song XM; Zhang BZ; Luo L; Xu PM; Zhao YN; Zhao YB; Cheng G
    Biol Trace Elem Res; 1997 Mar; 56(3):331-41. PubMed ID: 9197929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy.
    Sieja K; Talerczyk M
    Gynecol Oncol; 2004 May; 93(2):320-7. PubMed ID: 15099940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial.
    Tantipalakorn C; Srisomboon J; Thienthong H; Pantusart A; Suprasert P; Saereesongkhun C; Eamtang S; Sutthichat A; Pautad N
    J Med Assoc Thai; 2004 Feb; 87(2):119-25. PubMed ID: 15061293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
    Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
    Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
    Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial.
    Benoehr P; Krueth P; Bokemeyer C; Grenz A; Osswald H; Hartmann JT
    J Am Soc Nephrol; 2005 Feb; 16(2):452-8. PubMed ID: 15590762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.
    Nakazawa M; Ohnishi T; Ohmae M; Chisoku H; Yui S; Iwai S; Sumi T; Fukuda Y; Kishino M; Yura Y
    Int J Clin Pharmacol Res; 2005; 25(3):115-22. PubMed ID: 16366419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
    Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
    Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination chemotherapy with Taxol and cisplatin for 57 patients with non-small cell lung cancer by intraartery and intravenous infusion].
    Zhao Y; Wang SM; Zhang J
    Ai Zheng; 2002 Dec; 21(12):1365-7. PubMed ID: 12520750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
    Schmidinger M; Budinsky AC; Wenzel C; Piribauer M; Brix R; Kautzky M; Oder W; Locker GJ; Zielinski CC; Steger GG
    Wien Klin Wochenschr; 2000 Jul; 112(14):617-23. PubMed ID: 11008323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
    Morita S; Nakata B; Tsuji A; Mitachi Y; Shirasaka T; Saji S; Ohashi Y; Sakamoto J; Hirakawa K
    Jpn J Clin Oncol; 2007 Dec; 37(12):924-9. PubMed ID: 18211983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance and effects of intraperitoneal cisplatin administration for ovarian cancer].
    Shimizu A; Ookubo K; Hasegawa J; Endoh T; Fujiwara O; Yoda A; Okuyama D; Narabayashi A; Kimura T; Takahashi J; Notake Y
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1801-5. PubMed ID: 10560398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.